Marquette University

e-Publications@Marquette
Psychology Faculty Research and Publications

Psychology, Department of

1-2018

Benchmarking Treatment Response in Tourette’s Disorder: A
Psychometric Evaluation and Signal Detection Analysis of the
Parent Tic Questionnaire
Madeline M. Rasch
University of California - Los Angeles

Douglas W. Woods
Marquette University, douglas.woods@marquette.edu

Matthew W. Specht
Johns Hopkins University

John T. Walkup
Weill Cornell Medical College

Lawrence Scahill
Emory University

See next page for additional authors

Follow this and additional works at: https://epublications.marquette.edu/psych_fac
Part of the Psychology Commons

Recommended Citation
Rasch, Madeline M.; Woods, Douglas W.; Specht, Matthew W.; Walkup, John T.; Scahill, Lawrence; Wilhelm,
Sabine; Peterson, Alan L.; and Piacentini, John, "Benchmarking Treatment Response in Tourette’s
Disorder: A Psychometric Evaluation and Signal Detection Analysis of the Parent Tic Questionnaire"
(2018). Psychology Faculty Research and Publications. 284.
https://epublications.marquette.edu/psych_fac/284

Authors
Madeline M. Rasch, Douglas W. Woods, Matthew W. Specht, John T. Walkup, Lawrence Scahill, Sabine
Wilhelm, Alan L. Peterson, and John Piacentini

This article is available at e-Publications@Marquette: https://epublications.marquette.edu/psych_fac/284

Marquette University

e‐Publications@Marquette
Psychology Faculty Research and Publications/Department of Psychology
This paper is NOT THE PUBLISHED VERSION; but the author’s final, peer‐reviewed manuscript. The
published version may be accessed by following the link in the citation below.

Behavior Therapy, Vol. 49, No. 1 (2018): 46‐56. DOI. This article is © Elsevier and permission has been
granted for this version to appear in e‐Publications@Marquette. Elsevier does not grant permission for
this article to be further copied/distributed or hosted elsewhere without the express permission from
Elsevier.

Benchmarking Treatment Response in
Tourette’s Disorder: A Psychometric
Evaluation and Signal Detection Analysis of the
Parent Tic Questionnaire
Douglas Wood
Department of Psychology, Marquette University, Milwaukee WI

Abstract
This study assessed the psychometric properties of a parent‐reported tic severity measure, the Parent
Tic Questionnaire (PTQ), and used the scale to establish guidelines for delineating clinically significant
tic treatment response. Participants were 126 children ages 9 to 17 who participated in a randomized
controlled trial of Comprehensive Behavioral Intervention for Tics (CBIT). Tic severity was assessed
using the Yale Global Tic Severity Scale (YGTSS), Hopkins Motor/Vocal Tic Scale (HMVTS) and PTQ;
positive treatment response was defined by a score of 1 (very much improved) or 2 (much improved)
on the Clinical Global Impressions – Improvement (CGI‐I) scale. Cronbach’s alpha and intraclass
correlations (ICC) assessed internal consistency and test‐retest reliability, with correlations evaluating
validity. Receiver‐ and Quality‐Receiver Operating Characteristic analyses assessed the efficiency of

percent and raw‐reduction cutoffs associated with positive treatment response. The PTQ
demonstrated good internal consistency (α = 0.80 to 0.86), excellent test‐retest reliability (ICC = .84
to .89), good convergent validity with the YGTSS and HM/VTS, and good discriminant validity from
hyperactive, obsessive‐compulsive, and externalizing (i.e., aggression and rule‐breaking) symptoms. A
55% reduction and 10‐point decrease in PTQ Total score were optimal for defining positive treatment
response. Findings help standardize tic assessment and provide clinicians with greater clarity in
determining clinically meaningful tic symptom change during treatment.
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Chronic tic disorders (CTDs), including Tourette’s disorder (TD), are characterized by involuntary,
repetitive movements (i.e., motor tics) and/or vocalizations (i.e., vocal tics) that have persisted for
more than 1 year (American Psychiatric Association [APA], 2013). Tics generally first emerge in early
childhood, peaking in severity in early adolescence, and, in many cases, steadily declining through early
adulthood (Hallett, 2015). Among youth, CTDs are more common in males, with a ratio as high as 4:1
(Hallett, 2015; Robertson, 2012), and are prevalent at rates ranging from 0.4% to 3.8% (Knight et al.,
2012; Scahill, Specht, & Page, 2013). In addition to tics, youth with CTDs commonly present with
attention‐deficit/hyperactivity disorder (ADHD) and obsessive‐ compulsive disorder (OCD; Cavanna &
Rickards, 2013). Although CTDs are often associated with diminished quality of life (Cavanna et al.,
2013), behavioral and pharmacological interventions have both demonstrated efficacy in reducing tic
severity (Murphy, Lewin, Storch, & Stock, 2013; Piacentini et al., 2010).
In clinical research, tics are most commonly assessed using the Yale Global Tic Severity Scale (YGTSS;
Leckman et al., 1989). The YGTSS is a clinician‐rated interview measure of tic severity that takes 30 to
45 minutes to complete. Available evidence suggests a reduction of 25% to 35% or decrease of 6 to 7
points on the YGTSS is associated with positive treatment response to empirically supported
interventions among children and adults with CTDs (Jeon et al., 2013; Storch et al., 2011). Although
informative, the YGTSS is less commonly used in clinical practice as it requires administration by a
trained rater and may be time consuming (Chang, Himle, Tucker, Woods, & Piacentini, 2009). Indeed,
clinician‐rated measures are less favored in clinical practice due to the time burden (Boswell, Kraus,
Miller, & Lambert, 2015; Hatfield & Ogles, 2007) of administration, scoring, and interpretation
(Garland, Kruse, & Aarons, 2003).
A time‐efficient alternative to clinician ratings of tic severity are parent and self‐report rating scales.
These scales can be completed quickly in the waiting room prior to treatment visits. Although there are
several options for parent and/or self‐report rating scales (see McGuire et al. 2012 for a review), most
have noted limitations that constrain their use in either research or clinical practice (e.g., minimal
psychometric evaluation, lack of specificity to tic symptoms, absence of individual tic ratings, etc.). One
promising parent‐report measure of tic severity is the Parent Tic Questionnaire (PTQ; Chang et al.,
2009). The PTQ assesses tic severity in the past week, allowing for individual parent ratings of tic
presence or absence for 14 vocal tics and 14 motor tics. Additionally, the measure allows for separate
ratings of tic frequency and intensity, completed for each tic. Frequency ratings range from 1 to 4 with
the following anchors: weekly, daily, constantly, hourly. Intensity ratings range from 1 to 4, with higher
scores indicative of greater tic intensity. The frequency and intensity ratings can be summed to yield a
severity score ranging from 0 (i.e., tic is absent, thus no frequency or intensity ratings are given) to 8

for each tic. The PTQ includes subtotals for motor and vocal tic severity, which are summed to produce
a total tic score. In the only prior psychometric evaluation (Chang et al., 2009), the PTQ exhibited fair
to excellent internal consistency (α = .79 to .90), good to excellent 2‐week test‐retest reliability
(Interclass correlation coefficient; ICC = .72 to .84), strong convergent validity with other measures of
tic severity (r = .54 to .73), and discriminant validity, with correlations between the PTQ and YGTSS
remaining strong after controlling for symptoms of inattention (rs = .53 to .70) and OCD (rs = .45
to .66).
Although providing initial evidence for using the PTQ, this initial report had some limitations, including
a relatively small sample size (n = 40) and limited attention to discriminant validity of the PTQ. The
latter point is particularly important due to the common presence of co‐occurring psychiatric
conditions (e.g., OCD, ADHD, disruptive behavior) among youth with tic disorders. It is important to
ensure the PTQ distinguishes between tics and potentially co‐occurring behaviors (e.g., compulsions,
hyperactivity, aggression) that are distinct from tics but may appear similar in topography (Cath et al.,
2011; Schapiro, 2002). Finally, the prior study did not provide guidelines for using the PTQ to
determine a clinically meaningful response to treatment. The utilization of evidence‐based assessment
is important for a variety of reasons, including standardization of assessment, sharing treatment
progress with patients, and providing a valid indication of clinically meaningful treatment response
(Boswell et al., 2015; Lambert, 2013). These factors are especially important in the treatment of youth
with CTDs, as symptoms are chronic and infrequently remit following treatment. Thus, establishing the
PTQ as a valid and efficient measure of treatment response would address a crucial gap in the field.
This study conducted a comprehensive psychometric examination of the PTQ in a large sample and
investigated the optimal percent and raw reduction in PTQ Total scores associated with positive
treatment response. First, the internal consistency and test‐retest reliability of the PTQ was examined.
Second, the convergent and discriminant validity of the PTQ was investigated. Finally, the optimal
percent and raw reduction in PTQ Total Tic score was explored.

Method
Participants
Participants were 126 children and adolescents ages 9 to 17 (M = 11.73, SD = 2.32) with TD, Chronic
Motor Tic Disorder or Chronic Vocal Tic Disorder, who participated in a NIH‐funded randomized
controlled‐comparison of Comprehensive Behavioral Intervention for Tics (CBIT) and Psychoeducation
and Supportive Psychotherapy (PST) between 2004 and 2007. Participants were enrolled at three sites,
including University of California, Los Angeles (n = 45), Johns Hopkins University (n = 41), and University
of Wisconsin‐Milwaukee (n = 40), with support for data coding, therapist supervision, and data analysis
and management from the University of Texas Health Science Center, Massachusetts General
Hospital/Harvard Medical School, and Yale University, respectively. The gender distribution of the
sample was 78.6% male, and the racial background was 84.9% Caucasian, 7.1% Hispanic, 3.2% African‐
American, 3.2% Asian/Pacific Islander, and 1.6% other (see Table 1). Piacentini et al. (2010) and Specht
et al. (2011) provide additional information regarding sample characteristics and other aspects of the
original trial methodology.
Table 1. Demographic and Clinical Characteristics of the Full Sample

N = 126
Demographics
Age M(SD)
11.7 (2.3)
Male N(%)
99 (78.5)
Racial/Ethnic Minority N(%)
19 (15.1)
On Tic Meds N(%)
46 (36.6)
Tic Disorder Diagnosis N(%)
Tourette Syndrome
118 (93.7)
Chronic Motor Tic Disorder
7 (5.6)
Chronic Vocal Tic Disorder
1 (0.8)
Lifetime Comorbid Diagnosis N(%)
Attention Deficit Hyperactivity Disorder 15 (11.9)
Obsessive‐Compulsive Disorder
24 (19.0)
Generalized Anxiety Disorder
25 (19.8)
Social Phobia
27 (21.4)
Separation Anxiety Disorder
11 (8.7)
Baseline Tic Severity M(SD)
PTQ Total
36.11 (20.54)
PTQ Motor
32.78 (12.86)
PTQ Vocal
14.38 (10.99)
YGTSS Total
24.66 (6.06)
14.64 (3.78)
YGTSS Motor
YGTSS Vocal
10.02 (4.55)
Screening CBCL/6‐18 M(SD)
Externalizing Problems
48.96 (10.38)
Baseline CY‐BOCS M(SD)
Total
6.51 (7.79)
Compulsions
4.22 (4.91)
Screening ADHD RS‐IV M(SD)
Total
14.86 (12.24)
Hyperactivity Subscale
5.95 (5.92)
Note. CBCL/6‐18 = Child Behavior Checklist for Ages 6‐18; CY‐BOCS = CBCL 6‐18 = Children’s Yale‐Brown
Obsessive‐Compulsive Scale; ADHD RS‐IV = ADHD Rating Scale‐IV; The CBCL 6/18 and ADHD RS‐IV were not
administered at baseline.

Measures
Parent Tic Questionnaire (PTQ)
As previously described, the PTQ (Chang et al., 2009) is a parent‐rated tic severity scale assessing tic
frequency and intensity for individual tics, which sum to Motor Tic, Vocal Tic, and Total scores. Motor
Tic and Vocal Tic scores range from 0 to 112, and Total scores may range from 0 to 224.1 Within the
present sample, the actual range of baseline PTQ Total scores was 5 to 107 (M = 36.11; SD = 20.55),
with PTQ Total scores at week 10 ranging from 2 to 92 (M = 23.09; SD = 17.29). The PTQ has
demonstrated initial reliability and validity in a small sample, as described in the introduction (Chang et
al., 2009).

Yale Global Tic Severity Scale (YGTSS)
The YGTSS (Leckman et al., 1989) is a semistructured clinician‐rated instrument assessing motor and
vocal tic severity in the past week. Motor and vocal tics are rated separately (ranging from 0 to 5)
across five domains: number, frequency, intensity, complexity, and interference. The YGTSS produces a
Motor Tic score and Vocal Tic score each ranging from 0 to 25. The Motor and Vocal tic scores are
summed to yield a Total Tic score ranging from 0 to 50. The YGTSS has demonstrated excellent
interrater reliability (Walkup, Rosenberg, Brown, & Singer, 1992), fair to excellent stability (Storch et
al., 2005), and good convergent and discriminant validity (Leckman et al., 1989; Storch et al., 2005).

Hopkins Motor/Vocal Tic Scale (HM/VTS)
The HMVTS (Walkup, Rosenberg, Brown, & Singer, 1992) is a measure of severity of motor and vocal
tics over the past week. A modified version was used, wherein participants listed up to 5 motor tics and
5 vocal tics considered most bothersome. A clinician then rated each tic on a 0 (none) to 4 (severe)
scale, informally factoring in the patient and/or parent’s verbal report of tic frequency, intensity,
interference, and emotional distress. Tic ratings were summed to create composites for motor tic,
vocal tic, and total tic severity. The HM/VTS has good interrater reliability, good concurrent validity,
good divergence from ADHD, fair divergence from OCD (Walkup et al., 1992) and treatment sensitivity
(McGuire et al., 2015).

ADHD Rating Scale‐IV (ADHD RS‐IV)
The ADHD RS‐IV (DuPaul et al., 1998) is an 18‐item measure with parent and teacher versions, used to
assess ADHD symptom severity in the past week. Each item is categorized as either
Hyperactive/Impulsive or Inattentive and is rated from 0 (no symptoms) to 3 (severe symptoms) based
on clinician interview with the parent and child. The sum of these items ranges from 0 (no symptoms)
to 54 (the most severe symptoms), reflecting the patient’s overall ADHD symptom severity. The ADHD
RS‐IV possesses satisfactory interrater reliability, good internal consistency, excellent test‐retest
reliability, acceptable convergent and discriminant validity (Zhang et al., 2005), and strong predictive
validity of specific ADHD diagnostic status (Power et al., 1998).

Children’s Yale‐Brown Obsessive Compulsive Scale (CY‐BOCS)
The CY‐BOCS (Scahill et al., 1997) is a semistructured, clinician‐administered scale measuring the
presence and severity of obsessions and/or compulsions over the past week. The CYBOCS consists of a
5‐item obsession rating scale and a 5‐item compulsion rating scale. The sum of all 10 items provides a
CY‐BOCS Total score, with higher scores indicative of greater symptom severity. The CY‐BOCS
demonstrates good to excellent interrater reliability (Scahill et al., 1997; Storch et al., 2004), high
internal consistency (Storch et al., 2004), strong convergent validity, and adequate to good
discriminant validity (Scahill et al., 1997; Storch et al., 2004).

Child Behavior Checklist/6‐18 (CBCL/6‐18)
The CBCL/6‐18 (Achenbach & Rescorla, 2001) is a 118‐item parent/caregiver‐report questionnaire that
assesses a wide variety of emotional and behavioral problems experienced by youths. Behavior is rated
on a 3‐point Likert scale, with item responses corresponding to “Not True” (0), “Somewhat or
Sometimes True” (1), and “Very True or Often True” (2). The CBCL/6‐18 includes three overarching
scales, including Internalizing Problems, Externalizing Problems, and Total Problems. The measure also
includes the following syndrome subscales: Anxious/depressed, Withdrawn/depressed, Somatic
Complaints, Rule Breaking, Aggressive Behavior, Social Problems, Thought Problems, and Attention
Problems. Of interest in the present analysis was the Externalizing Problems subscale (comprised of
Rule Breaking and Aggressive Behavior subscales). Raw scores are converted to age‐ and gender‐
normed T scores, with scores of 60 or greater on the overarching scales and 70 or greater on the
syndrome subscales indicative of clinically significant symptoms. The CBCL/6‐18 has evidenced strong
psychometric properties, including high test‐retest reliability (ICC = .95 for specific problem items), high
internal consistency (α = .78 to.97), good convergent and discriminant validity, and a factor structure
supporting its subscales (Achenbach & Rescorla, 2001).

Clinical Global Impression – Improvement Scale (CGI‐I)
The CGI‐I (Guy, 1976) is a clinician‐rated instrument designed to assess global improvement in
functioning following illness. A version of this scale, modified to assess global tic‐related impairment
and commonly used as a primary outcome measure in trials involving patients with TD (e.g., Piacentini
et al., 2010; Scahill et al., 2001; Wilhelm et al., 2012), was used. Clinicians rate the perceived patient
global improvement in tic‐related impairment according to the following 7‐point scale: Very Much
Improved (1), Much Improved (2), Improved (3), Minimally Improved (4), No change (5), Minimally
worse (6), and Very Much Worse (7). A score of 1 or 2 was used to classify positive treatment response
in the original trial (Piacentini et al., 2010).

Treatments
CBIT and PST were administered by trained clinicians with a master’s degree or higher during the acute
treatment period. CBIT is a multicomponent behavioral treatment protocol designed to reduce tic
severity (Woods et al., 2008). The primary component of CBIT is Habit Reversal Training (HRT), which
consists of several techniques including, most prominently, awareness training, competing response
training, and social support. The goal of HRT is to enhance awareness of premonitory urges and tic

occurrence, train the use of a behavior that is physically incompatible with tic occurrence, and
encourage use of these techniques with parental praise and prompting (Woods et al., 2008). A second
core component of CBIT is function‐based assessment and intervention, with the goal of identifying
settings, events, affective states, and social reactions exacerbating symptoms, and reducing the impact
of these stimuli on tic symptoms. CBIT also includes relaxation techniques (diaphragmatic breathing,
progressive muscle relaxation), a behavioral reward system, and relapse prevention strategies. PST
included psychoeducation and discussion of issues relevant to tics, with no direct tic intervention. Both
interventions included two initial 90‐minute sessions followed by six 60‐minute sessions, with the first
six occurring weekly and the final two each occurring in 2‐week intervals (Piacentini et al., 2010).

Independent evaluator training
Assessments were administered by master’s‐level or higher independent evaluators (IE), who were
trained to criterion, certified, and monitored according to procedures outlined in the trial (Piacentini et
al., 2010). Training on clinician‐rated assessment was directed by experts, LS and JW, and involved
providing co‐ratings of three videotaped YGTSS and CYBOCS assessments and CGI‐I ratings of three
written case vignettes. IEs were required to score within 15% of the expert’s rating on the YGTSS and
CYBOCS and within 15% of the group mean for all IEs undergoing training. IEs were also required to
score within 1 point of the expert’s rating on the CGI‐I, with 100% cross‐IE agreement required on no
fewer than two of the four ratings. Cross‐site reliability was maintained through IE supervision at each
study site and during bi‐weekly cross‐site conference calls. Additionally, 13% of assessment video
recordings were randomly selected for co‐rating by the quality assurance site, yielding good reliability
and no cross‐site variability.

Procedure
Following completion of IRB‐approved consent and assent procedures, IEs blinded to treatment
condition screened youth for study eligibility. Participants were included in the trial based on a DSM‐
IV‐TR (APA, 2000) diagnosis of TD or CTD (i.e., chronic motor tic disorder or chronic vocal tic disorder),
established through administration of the Anxiety Disorders Interview Schedule – Research Lifetime
Version (Silverman & Albano, 2002), a modified version of the Anxiety Disorders Interview Schedule
(Silverman & Albano, 1996), which included added modules on chronic tic disorders, and several other
psychiatric disorders; moderate tic severity as evidenced by a YGTSS score ≥ 14 for TD and ≥ 10 for
CTD; fluency in English; and intellectual functioning in the low average range or higher (IQ score > 80),
determined through administration of the Wechsler Abbreviated Scale of Intelligence.
Psychotropic medications were allowed provided participants had been on a stable dosage at least 6
weeks prior to study entry and no changes in dosage were planned during the course of study
participation. Individuals were excluded based on a lifetime diagnosis of psychosis, mania, or pervasive
developmental disorder, current diagnosis of substance abuse or dependence, any medical condition
interfering in study participation, and 4 or more prior sessions of behavior therapy for tics. Eligible
participants received a baseline assessment 7 to 10 days following screening, and were randomized to
receive either CBIT or PST. Participants received mid‐ (5 week) and posttreatment (10 week)
assessments during a 10‐week acute treatment period (Piacentini et al., 2010). IE‐administered
interview measures (YGTSS, CY‐BOCS, HM/VTS) were completed with the child and parent
concurrently. The CGI‐I was completed by an IE based on clinical judgment of improvement in tic‐

related impairment. The parent completed the PTQ, CBCL, and ADHD RS‐IV. With respect to the timing
of administration of instruments used in the present analysis, the YGTSS, ADHD RS‐IV, CBCL, and PTQ
were administered at screening; the YGTSS, CY‐BOCS, HM/VTS, and PTQ were administered at baseline
and week 5 assessments, with the CGI‐I and ADHD RS‐IV also completed at week 5. All measures of
interest were re‐administered at week 10 (posttreatment).

Analytic Plan
In the present study, Cronbach’s alpha and ICC calculated internal consistency and test‐retest reliability
of the PTQ Total tic score, respectively. For internal consistency, α values ≥ .90 were considered
excellent, .80 to .89 were considered good, .70 to .79 were considered fair, and < .70 poor (Cicchetti,
1994). Meanwhile, ICC of .75 to 1.00 was indicative of excellent test‐retest reliability, values of .60
to .74 signified good reliability, coefficients ranging from .40 to .59 indicated poor agreement, and
< .40 was considered poor agreement (Cicchetti, 1994). Second, Pearson correlations examined the
convergent and discriminant validity of the PTQ Total tic score. A correlation value of > .50 between
the PTQ and other measures of tic severity indicated good convergent validity. Correlations of .30
to .49 and .10 to .29 represented fair and poor convergent validity, respectively. Good discriminant
validity was represented by correlations of .10 to .29 between the PTQ and measures that did not
assess tic severity. Correlation values that exceeded this range were considered fair (.30 to .49) and
poor (> .50) discriminant validity (Cicchetti, 1994). Finally, a receiver operating characteristic (ROC)
assessed a range of percentage and raw reduction PTQ Total tic score cutoffs in relation to treatment
responder status using the CGI‐I scale. The PTQ Total tic scores were divided into raw reduction cutoff
scores in 2‐point increments and raw percent reduction cutoffs (set by 5‐point increments). We
performed ROC curves, plotting sensitivity, or true positive rate, referring to the proportion of
treatment responders obtaining scores above various percent and raw reduction cutoffs on the y‐axis,
and false positive rate (1‐specificity), referring to the proportion of treatment responders who failed to
obtain scores above cutoffs on the x‐axis (Swets, 1996). Sensitivity and false positive rates for each
cutoff were used in conjunction with formulas by Kraemer and colleagues (Kraemer, Periyakoil, &
Noda, 2002) to establish specificity (the rate of nontreatment responders who did not score above
various cutoffs), positive predictive value (proportion of participants with raw or percent reductions
above various PTQ cutoffs who were classified as treatment responders), negative predictive value
(rate of participants not exceeding PTQ cutoffs who were identified as nontreatment responders), and
efficiency (the concordance rate between cutoffs and treatment responder status; Glaros & Kline,
1988; Lalken & McClusky, 2008). Youden Index J (sensitivity – specificity – 1), a common ROC curve
summary statistic, was also calculated, as it provides an optimal cutoff point for establishing a given
test’s ability to discriminate between diagnostic groups when sensitivity and specificity are equally
considered (Youden, 1950).
Although ROC analysis is highly useful for diagnostic decision making, it has several limitations. First,
sensitivity and specificity assess the proportion of patients correctly categorized but do not assess the
ability of a test to differentiate between diagnostic groups; and second, due to their properties,
sensitivity and specificity values lack an interpretive statistical scale of reference (Gilchrist, 1992). To
address these limitations and provide additional ROC interpretive measures, Quality Receiver
Operating Characteristic (QROC) analysis was performed. QROC analysis rescales sensitivity and
specificity values to weighted kappa coefficients or quality values, which provide a standardized
measure of ROC values (Kraemer et al., 2002; Moore, Andlauer, Simon, & Mignot, 2014). Specific kappa

coefficients calculated in the present analysis include rescaled measures of sensitivity (k1), specificity
(k0), and efficiency (k0.5; Gilchrist, 1992).

Results
Internal Consistency
The internal consistency for the PTQ Motor tic score (α = .82; α = .81), PTQ Vocal tic score (α = .80, α
= .83), and PTQ Total tic score (α = .86; α = .86) were good at the screening and baseline visits,
respectively.

Test‐Retest Reliability
Test‐retest reliability between screening and baseline administrations of the PTQ Motor tic score (ICC
= .84; 95% CI = .76 to .89), PTQ Vocal tic score (ICC = .85; 95% CI = .77 to .90), and PTQ Total tic score
(ICC = .89; 95% CI = .84 to .92) were excellent.

Convergent Validity
Across screening and baseline assessments correlations between the PTQ and YGTSS for PTQ Motor tic
and YGTSS Motor tic scores (r = .62, p < .001; r = .66, p < .001), PTQ Vocal tic and YGTSS Vocal tic scores
(r = .53, p < .001; r = .58, p < .001), and PTQ Total tic and YGTSS Total tic scores (r = .68, p < .001; r = .64,
p < .001) were indicative of good convergent validity. Convergence between baseline PTQ and HM/VTS
ratings was good for the PTQ Motor tic score and HM/VTS Motor tic severity composite (r = .50, p
< .001); PTQ Vocal tic score and HM/VTS Vocal tic severity composite (r = .64, p < .001); and PTQ Total
tic score and HM/VTS Total tic severity composite (r = .61, p < .001).

Discriminant Validity
At the screening assessment the PTQ Total tic score did not significantly correlate with the ADHD RS‐IV
Hyperactivity score (r = .14, p = .15) or ADHD RS‐IV Total score (r = .14 p = .14). Correlations were also
not significant for the ADHD RS‐IV scores and PTQ Motor tic (r = .11‐0.12, ps = .19‐.24) and Vocal tic
scores (r = .06‐.08, ps = .41‐.57), indicating good discriminance between scales. Additionally, there was
good discriminance between baseline PTQ Total tic scores, CY‐BOCS Total scores (r = .16, p = .09), and
CY‐BOCS Compulsion scores (r = .10, p = .30). At the screening assessment, the PTQ Motor Tic score (r
= .09, p = .38), PTQ Vocal Tic score (r = .12, p = .24) and PTQ Total Tic score (r = .12, p = .19) exhibited
good discriminance from the CBCL/6‐18 Externalizing T score.

Inter‐Scale Correlations
Inter‐scale correlations between the screening administration of the PTQ Total Tic score and PTQ
Motor Tic (r = .90, p < .001) and Vocal Tic (r = .79 p < .001) scores were strong. The correlation between
PTQ Motor Tic and Vocal Tic scores at screening was fair (r = .47, p < .001). At baseline, inter‐scale
correlations between the PTQ Total Tic score and PTQ Motor Tic (r = .86, p < .001) and Vocal Tic (r
= .81, p < .001) scores were also strong. The correlation between baseline PTQ Motor and Vocal Tic
scores was (r = .45, p < .001) fair.

Predicting Positive Treatment Response Using ptq Total Percentage Reduction
Forty‐four participants (34.9%) within the sample were classified as treatment responders on the CGI‐I
at the 10‐week posttreatment assessment. A ≥ 55% reduction in PTQ Total score yielded the highest
rescaled efficiency score (k0.5 = .52), indicative of a 52% likelihood of concordance between the ≥ 55%
reduction cutoff and CGI‐I rating. The cutoff of 52% yielded the highest Youden Index J score (.50),
indicating this cutoff provides the most optimal balance between sensitivity (.61) and specificity (.89).
The positive predictive and negative predictive values at this cutoff were both acceptable at .78 each.
However, a decrease in PTQ Total of ≥ 45% yielded similar rescaled efficiency (k0.5 = .48) and Youden
Index J (.49) scores. See Table 2 and Figure 1 for QROC analyses of PTQ percent reduction cutoffs
predicting treatment responder status.
Table 2. Predicting Positive Treatment Response From Parent Tic Questionnaire Total Score Percent Reduction
Cutoffs

PTQ Total Tic
Score Percent
Reduction
Cutoff
≥5
≥ 10
≥ 15
≥ 20
≥ 25
≥ 30
≥ 35
≥ 40
≥ 45
≥ 50
≥ 55
≥ 60
≥ 65
≥ 70
≥ 75
≥ 80
≥ 85
≥ 90
≥ 95

Sensitivity Specificity
.95
.95
.90
.90
.85
.81
.76
.76
.71
.63
.61
.54
.46
.44
.39
.24
.20
.12
.00

.35
.43
.49
.52
.59
.64
.65
.70
.78
.83
.89
.91
.91
.91
.94
.97
.98
1.00
1.00

Positive
Predictive
Value
.48
.51
.53
.54
.57
.58
.58
.61
.67
.69
.78
.78
.75
.74
.80
.83
.88
1.00

Negative
Predictive
Value
.92
.93
.89
.89
.86
.84
.81
.82
.81
.78
.78
.76
.73
.72
.71
.67
.66
.64

Efficiency k1 k0 k0.5
.58
.63
.65
.67
.69
.70
.69
.72
.75
.75
.78
.76
.73
.72
.73
.69
.68
.66

.79 .16 .26
.83 .21 .33
.72 .24 .36
.74 .26 .39
.66 .30 .41
.59 .32 .42
.51 .32 .39
.54 .37 .44
.51 .46 .48
.44 .51 .47
.45 .64 .52
.37 .64 .47
.30 .60 .40
.28 .59 .38
.25 .67 .36
.15 .73 .25
.12 .81 .21
.08 .99 .15

Youden
Index J
.3
.38
.39
.43
.44
.44
.41
.45
.49
.46
.50
.44
.37
.34
.33
.21
.18
.12

Figure 1. Efficiency (k0.5) for Parent Tic Questionnaire Total tic score percent reduction cutoffs predicting positive
treatment response.

Predicting Positive Treatment Response Using ptq Total Raw Score Reduction
A raw PTQ Total reduction of ≥ 10 points yielded optimal rescaled efficiency (k0.5 = .41), indicating a
41% chance of agreement between the 10‐point reduction cutoff and CGI‐I rating. This cutoff yielded a
Youden Index J score of .43, representing maximum equivalence between sensitivity (.78) and
specificity (.65). A positive predictive value of .58 and negative predictive value of .82 were found at
this cutoff. See Table 3 and Figure 2 for QROC analyses of PTQ raw reduction cutoffs defining positive
treatment response.
Table 3. Predicting Positive Treatment Response From Parent Tic Questionnaire Total Tic Score Raw Reduction
Cutoffs

PTQ Total
Tic Score Raw
Reduction
Cutoff
≥2
≥4
≥6
≥8
≥ 10
≥ 12
≥ 14
≥ 16
≥ 18
≥ 20

Sensitivity Specificity
.95
.85
.81
.81
.78
.68
.63
.59
.59
.51

.35
.41
.52
.57
.65
.68
.73
.75
.76
.79

Positive
Predictive
Value
.48
.48
.52
.54
.58
.58
.60
.59
.61
.61

Negative
Predictive
Value
.92
.82
.81
.82
.82
.77
.76
.74
.74
.72

Efficiency k1 k0 k0.5
.58
.58
.63
.66
.70
.68
.69
.68
.69
.69

.12 .23 .26
.11 .24 .24
.19 .32 .30
.25 .36 .35
.34 .42 .41
.26 .37 .36
.27 .38 .36
.23 .35 .34
.25 .36 .35
.20 .32 .32

Youden
Index J
.3
.27
.33
.38
.43
.37
.36
.33
.35
.31

PTQ Total
Tic Score Raw
Reduction
Cutoff
≥ 22
≥ 24
≥ 26
≥ 28
≥ 30
≥ 32
≥ 34
≥ 36
≥ 38
≥ 40

Sensitivity Specificity
.46
.42
.34
.29
.20
.17
.17
.17
.12
.12

.83
.86
.91
.91
.92
.92
.92
.92
.94
.95

Positive
Predictive
Value
.62
.65
.69
.70
.61
.58
.58
.58
.55
.62

Negative
Predictive
Value
.71
.70
.69
.67
.65
.64
.64
.64
.63
.63

Efficiency k1 k0 k0.5
.69
.69
.69
.67
.64
.63
.63
.63
.62
.63

.18 .30 .31
.16 .27 .29
.13 .23 .27
.09 .19 .22
.03 .10 .13
.02 .08 .11
.02 .08 .11
.02 .08 .11
.01 .05 .07
.01 .05 .09

Youden
Index J
.29
.27
.25
.20
.12
.09
.09
.09
.06
.07

Figure 2. Efficiency (k0.5) for Parent Tic Questionnaire Total tic score raw reduction cutoffs predicting positive
treatment response.

Discussion
Given the time burden and limited utilization of clinician‐rated measures to monitor treatment
response in clinical practice, this study examined the psychometric properties of the PTQ and
conducted a signal detection analysis to assess the efficiency of tic severity reduction cutoffs
associated with positive treatment response. The PTQ was found to have good internal consistency
and excellent test‐retest reliability. Additionally, the PTQ exhibited strong convergent validity with
clinician‐rated measures of tic severity, and strong discriminant validity from constructs that frequently
co‐occur with tics but are distinct (e.g., ADHD symptom severity, OCD symptom severity, severity of
externalizing problems, including defiant behavior and aggression). Additionally, the PTQ showed
strong inter‐scale correlations between the total score and motor and vocal subtotals. Understandably,

correlations between motor and vocal subscales of the PTQ were weaker, as the two independent
scales are combined to yield a total score. These findings are consistent with the initial psychometric
investigation of the PTQ, which showed high internal consistency, good to excellent test‐retest
reliability, excellent convergent validity with the YGTSS, and preliminary evidence of discriminant
validity from symptoms of inattention and OCD (Chang et al., 2009). However, this report extends this
initial psychometric investigation by utilizing a larger treatment‐seeking clinical sample, and
investigating discriminant validity using a broad array of comorbid constructs (e.g., internalizing and
externalizing symptoms). Findings were also consistent with the initial psychometric investigation of
the adult version of this scale, the Adult Tic Questionnaire, which shows strong psychometric
properties (Abramovitch et al., 2015).
In addition, this report examined the efficiency of tic severity reduction cutoffs associated with positive
treatment response. The signal detection analyses identified a 55% reduction in the PTQ Total score as
optimal for defining positive treatment response, with a range from 45% to 55% being most
representative of positive treatment response. When examining raw‐score reductions, a 10‐point
reduction in the PTQ total tic score was maximally indicative of positive clinical response. Notably,
these differences are larger than prior studies, which have found a 25% to 35% (or 6‐to‐7 point)
reduction in total tic severity on the YGTSS to correspond with a positive treatment response (Jeon et
al., 2013; Storch et al., 2011). The difference in percent reduction between scales may be related to the
high range of PTQ scores relative to the YGTSS. Alternatively, differences may be related to
discrepancies between parent and clinician perspectives. Furthermore, differences may be attributed
to distinctions in the structure of YGTSS and PTQ scales. Specifically, the YGTSS assesses tic severity
across five domains (i.e., number, frequency, intensity, complexity, interference), whereas the PTQ
takes into account tic number, frequency, and intensity. While the YGTSS is still considered to be the
gold‐standard measure to evaluate tic severity in clinical research, it requires considerable training and
time to administer. Comparatively, the PTQ offers advantages over the YGTSS in clinical practice due to
its strong psychometric properties and ease of administration. Moreover, the present findings provide
optimal benchmarks to help clinicians establish positive response to treatment for tics, thereby
increasing the utility of the scale.
Findings should be considered within the context of study limitations. First, the PTQ is a heterogeneous
measure with ratings varying considerably across patients depending on tic classification (i.e., motor
and/or vocal) and number endorsed within the past week. Therefore, ratings are more meaningful
when used to track symptoms over time within cases rather than used as a comparative benchmark of
overall tic severity across youth with CTDs. Second, generalizability of our findings to the broader
population of youth with tics may be limited by the demographics of our sample (i.e., predominantly
Caucasian), and the context (i.e., research setting) within which the study was conducted. However,
the demographics, clinical characteristics, and settings are largely consistent with other treatment
studies of youth with CTDs. Additionally, the brevity of the 7‐to‐10 day test‐retest reliability window—
used in the context of a treatment trial—may have influenced participant ratings. Moreover, as tic
listings differed between participants, many tics were rated as absent in the past week, resulting in
frequency and intensity ratings of 0. Therefore, internal consistency outcomes should be interpreted
cautiously. Finally, due to the heterogeneity in tic symptom presentation across participants, multiple
factors may have influenced IE ratings of treatment response. For example, in some cases those rated
as positive treatment responders may have had significant reductions in one or two tics, while in other
cases individuals may have experienced general reductions across all tics.

Within the past decade, researchers have worked to disseminate empirically supported behavioral
treatment for tics into standard clinical practice. As utilization of behavior therapy for tics in
community practice expands, so will the need for reliable, standardized measures to assess tic
symptom change over time. Although the YGTSS continues to serve as the gold‐standard measure to
assess tic severity, there are several pragmatic limitations that constrain its use across clinical settings.
Comparatively, our findings establish the PTQ as an efficient and psychometrically sound instrument
for use with parents of children with TD symptoms of a moderate or worse nature (i.e., those with mild
symptoms were not included in the clinical trial). Moreover, we have outlined benchmarks for
assessing clinically meaningful symptom change in youth undergoing treatment for CTDs using the
PTQ. This is particularly relevant for treatment of tics as remission is rare; thus, guidelines will allow
clinicians to empirically assess therapeutic response even when tic symptoms persist. Thus, the
combination of strong psychometric properties, ease of administration, and clinical benchmarks for
treatment improvement facilitate the utility of the PTQ for monitoring treatment response in clinical
practice.
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